Unknown

Dataset Information

0

Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.


ABSTRACT: GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist of GPR40. In this report, we present the discovery of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure-activity relationships leading to more potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.

SUBMITTER: Wang Y 

PROVIDER: S-EPMC4027505 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist of GPR40. In this report, we present the discovery of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure-activity relationships leading to more potent agonists such as AM-5262 (26) with improved rat PK profile and gen  ...[more]

Similar Datasets

| S-EPMC4025659 | biostudies-literature
| S-EPMC4027632 | biostudies-literature
| S-EPMC3467217 | biostudies-literature
| S-EPMC4027784 | biostudies-other
| S-EPMC7072329 | biostudies-literature
| S-EPMC6047174 | biostudies-literature
| S-EPMC4360146 | biostudies-literature
| S-EPMC4007909 | biostudies-other
| S-EPMC9234963 | biostudies-literature
| S-EPMC6021034 | biostudies-literature